Altana submits roflumilast in Europe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daxas (roflumilast) marketing authorization application has been submitted to the European Medicines Evaluation Agency, Altana announces Feb. 13. In the U.S., the oral, once-daily, selective phosphodiesterase-4 inhibitor is in Phase III for treatment of chronic obstructive pulmonary disease and asthma with development partner Pfizer...